Levamisole showed no clear difference in adverse effects: infection compared with cyclophosphamide (low certainty).
Levamisole showed no clear difference in adverse effects: leucopenia compared with cyclophosphamide (low certainty).
It is very uncertain whether levamisole changes adverse effects: abnormal liver function tests compared with cyclophosphamide (very low certainty).
Cyclosporin plus prednisolone may leads to lower relapse at 6 months compared with prednisolone alone (low certainty).
The review found no eligible studies for this question.
Cyclosporin plus prednisolone showed no clear difference in relapse at 12 months compared with prednisolone alone (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether cyclosporin plus prednisolone changes adverse effects: number needing cytotoxic agents compared with prednisolone alone (very low certainty).
Alkylating agents showed no clear difference in relapse at end of therapy (6 to 9 months) compared with cyclosporin (low certainty).
Alkylating agents may leads to lower relapse at 12 to 24 months compared with cyclosporin (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Alkylating agents showed no clear difference in adverse effects: serum creatinine compared with cyclosporin (low certainty).
The review found no eligible studies for this question.
Alkylating agents may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).
Alkylating agents may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).
It is very uncertain whether alkylating agents changes adverse effects: hypertension compared with cyclosporin (very low certainty).
It is very uncertain whether alkylating agents changes adverse effects: leucopenia compared with cyclosporin (very low certainty).